Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Short- and Long-Term Pharmacologic Measures of HIV Pre-exposure Prophylaxis Use Among High-Risk Men Who Have Sex With Men in HPTN 067/ADAPT.

Velloza J, Bacchetti P, Hendrix CW, Murnane P, Hughes JP, Li M, Curlin ME, Holtz TH, Mannheimer S, Marzinke MA, Amico KR, Liu A, Piwowar-Manning E, Eshleman SH, Dye BJ, Gandhi M, Grant RM; HPTN 067/ADAPT Study Team.

J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):149-158. doi: 10.1097/QAI.0000000000002128.

2.

Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.

Keller MJ, Wood L, Billingsley JM, Ray LL, Goymer J, Sinclair S, McGinn AP, Marzinke MA, Frank B, Srinivasan S, Liu C, Atrio JM, Espinoza L, Mugo N, Spiegel HML, Anderson PL, Fredricks DN, Hendrix CW, Marrazzo J, Bosinger SE, Herold BC.

Lancet HIV. 2019 Aug;6(8):e498-e508. doi: 10.1016/S2352-3018(19)30145-6. Epub 2019 Jul 15.

PMID:
31320290
3.

Incentives for Viral Suppression in People Living with HIV: A Randomized Clinical Trial.

Silverman K, Holtyn AF, Rodewald AM, Siliciano RF, Jarvis BP, Subramaniam S, Leoutsakos JM, Getty CA, Ruhs S, Marzinke MA, Fingerhood M.

AIDS Behav. 2019 Sep;23(9):2337-2346. doi: 10.1007/s10461-019-02592-8.

PMID:
31297681
4.

Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.

Mallayasamy S, Chaturvedula A, Fossler MJ, Sale M, Goti V, Bumpus NN, Marzinke MA, Hendrix CW, Haberer JE; Partners Demonstration Project Team.

Antimicrob Agents Chemother. 2019 Jul 25;63(8). pii: e00446-19. doi: 10.1128/AAC.00446-19. Print 2019 Aug.

PMID:
31182536
5.

2-Hydroxypropyl-β-cyclodextrin-enhanced pharmacokinetics of cabotegravir from a nanofluidic implant for HIV pre-exposure prophylaxis.

Pons-Faudoa FP, Sizovs A, Di Trani N, Paez-Mayorga J, Bruno G, Rhudy J, Manohar M, Gwenden K, Martini C, Chua CYX, Varchi G, Marzinke MA, Grattoni A.

J Control Release. 2019 Jul 28;306:89-96. doi: 10.1016/j.jconrel.2019.05.037. Epub 2019 May 25.

PMID:
31136811
6.

Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings.

Thurman AR, Schwartz JL, Ravel J, Gajer P, Marzinke MA, Yousefieh N, Anderson SM, Doncel GF.

PLoS One. 2019 May 20;14(5):e0217229. doi: 10.1371/journal.pone.0217229. eCollection 2019.

7.

Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide.

Cerrone M, Alfarisi O, Neary M, Marzinke MA, Parsons TL, Owen A, Maartens G, Pozniak A, Flexner C, Boffito M.

J Antimicrob Chemother. 2019 Jun 1;74(6):1670-1678. doi: 10.1093/jac/dkz068.

PMID:
30815689
8.

Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial.

Marrazzo JM, Rabe L, Kelly C, Richardson B, Deal C, Schwartz JL, Chirenje ZM, Piper J, Morrow RA, Hendrix CW, Marzinke MA, Hillier SL; VOICE Study Team.

J Infect Dis. 2019 May 24;219(12):1940-1947. doi: 10.1093/infdis/jiz045.

PMID:
30753642
9.

Pharmacokinetics of Dapivirine Transfer into Blood Plasma, Breast Milk, and Cervicovaginal Fluid of Lactating Women Using the Dapivirine Vaginal Ring.

Noguchi LM, Hoesley C, Kelly C, Scheckter R, Bunge K, Nel A, Marzinke MA, Hendrix CW, Dezzutti CS, Hillier SL, Bogen DL, Piper JM, Beigi RH.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e01930-18. doi: 10.1128/AAC.01930-18. Print 2019 Mar.

10.

The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.

McGowan I, Wilkin T, Landovitz RJ, Wu C, Chen Y, Marzinke MA, Hendrix CW, Richardson P, Eshleman SH, Andrade A, Chege W, Anderson PL, McCauley M, Farley J, Mayer KH, Anton P, Brand RM, Cranston RD, Gulick R.

AIDS. 2019 Feb 1;33(2):237-246. doi: 10.1097/QAD.0000000000002038.

PMID:
30557160
11.

Predictors of Daily Adherence to HIV Pre-exposure Prophylaxis in Gay/Bisexual Men in the PRELUDE Demonstration Project.

Vaccher SJ, Marzinke MA, Templeton DJ, Haire BG, Ryder N, McNulty A, Foster R, Grulich AE, Zablotska IB; PRELUDE Study Team; NSW HIV Prevention Partnership Project.

AIDS Behav. 2019 May;23(5):1287-1296. doi: 10.1007/s10461-018-2353-5.

PMID:
30523489
12.

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.

Landovitz RJ, Li S, Grinsztejn B, Dawood H, Liu AY, Magnus M, Hosseinipour MC, Panchia R, Cottle L, Chau G, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, Zhang Y, Tolley E, Sugarman J, Kofron R, Adeyeye A, Burns D, Rinehart AR, Margolis D, Spreen WR, Cohen MS, McCauley M, Eron JJ.

PLoS Med. 2018 Nov 8;15(11):e1002690. doi: 10.1371/journal.pmed.1002690. eCollection 2018 Nov.

13.

Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women.

Chen BA, Zhang J, Gundacker HM, Hendrix CW, Hoesley CJ, Salata RA, Dezzutti CS, van der Straten A, Hall WB, Jacobson CE, Johnson S, McGowan I, Nel AM, Soto-Torres L, Marzinke MA; MTN-024/IPM 031 Protocol Team for the Microbicide Trials Network .

Clin Infect Dis. 2019 Mar 19;68(7):1144-1151. doi: 10.1093/cid/ciy654.

14.

Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.

Vincent KL, Moss JA, Marzinke MA, Hendrix CW, Anton PA, Pyles RB, Guthrie KM, Dawson L, Olive TJ, Butkyavichene I, Churchman SA, Cortez JM Jr, Fanter R, Gunawardana M, Miller CS, Yang F, Rosen RK, Vargas SE, Baum MM.

PLoS Med. 2018 Sep 28;15(9):e1002655. doi: 10.1371/journal.pmed.1002655. eCollection 2018 Sep.

15.

Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc.

Vincent KL, Moss JA, Marzinke MA, Hendrix CW, Anton PA, Gunawardana M, Dawson LN, Olive TJ, Pyles RB, Baum MM.

PLoS One. 2018 Aug 22;13(8):e0201952. doi: 10.1371/journal.pone.0201952. eCollection 2018.

16.

FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir.

Bunge KE, Dezzutti CS, Hendrix CW, Marzinke MA, Spiegel HML, Moncla BJ, Schwartz JL, Meyn LA, Richardson-Harman N, Rohan LC, Hillier SL.

J Int AIDS Soc. 2018 Aug;21(8):e25156. doi: 10.1002/jia2.25156.

17.

Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis.

Chua CYX, Jain P, Ballerini A, Bruno G, Hood RL, Gupte M, Gao S, Di Trani N, Susnjar A, Shelton K, Bushman LR, Folci M, Filgueira CS, Marzinke MA, Anderson PL, Hu M, Nehete P, Arduino RC, Sastry JK, Grattoni A.

J Control Release. 2018 Sep 28;286:315-325. doi: 10.1016/j.jconrel.2018.08.010. Epub 2018 Aug 6.

18.

Elevated creatinine in a patient on IVIG-therapy.

Knezevic CE, Ness MA, Kratz LE, Marzinke MA.

Clin Chim Acta. 2018 Nov;486:94-97. doi: 10.1016/j.cca.2018.07.038. Epub 2018 Jul 21.

PMID:
30040921
19.

Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention.

Heffron R, Mugo N, Hong T, Celum C, Marzinke MA, Ngure K, Asiimwe S, Katabira E, Bukusi EA, Odoyo J, Tindimwebwa E, Bulya N, Baeten JM; Partners Demonstration Project and the Partners PrEP Study Teams.

AIDS. 2018 Jul;32(12):1707-1713. doi: 10.1097/QAD.0000000000001867.

20.

Fecal Coliform Bacterial Detection to Assess Enema Adherence in HIV Prevention Clinical Studies.

Aung WS, Bakshi RP, Breakey J, Johnson JE, Hendrix CW, Weld E, Fuchs EJ, Marzinke MA.

AIDS Behav. 2019 Jan;23(1):252-258. doi: 10.1007/s10461-018-2211-5.

PMID:
29971733
21.

Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women.

Thurman AR, Schwartz JL, Brache V, Clark MR, McCormick T, Chandra N, Marzinke MA, Stanczyk FZ, Dezzutti CS, Hillier SL, Herold BC, Fichorova R, Asin SN, Rollenhagen C, Weiner D, Kiser P, Doncel GF.

PLoS One. 2018 Jun 28;13(6):e0199778. doi: 10.1371/journal.pone.0199778. eCollection 2018.

22.

Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.

Pyra M, Anderson PL, Hendrix CW, Heffron R, Mugwanya K, Haberer JE, Thomas KK, Celum C, Donnell D, Marzinke MA, Bukusi EA, Mugo NR, Asiimwe S, Katabira E, Baeten JM; Partners Demonstration Study Team.

AIDS. 2018 Aug 24;32(13):1891-1898. doi: 10.1097/QAD.0000000000001922.

23.

Quality Control Practices for Chemistry and Immunochemistry in a Cohort of 21 Large Academic Medical Centers.

Rosenbaum MW, Flood JG, Melanson SEF, Baumann NA, Marzinke MA, Rai AJ, Hayden J, Wu AHB, Ladror M, Lifshitz MS, Scott MG, Peck-Palmer OM, Bowen R, Babic N, Sobhani K, Giacherio D, Bocsi GT, Herman DS, Wang P, Toffaletti J, Handel E, Kelly KA, Albeiroti S, Wang S, Zimmer M, Driver B, Yi X, Wilburn C, Lewandrowski KB.

Am J Clin Pathol. 2018 Jul 3;150(2):96-104. doi: 10.1093/ajcp/aqy033.

PMID:
29850771
24.

Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing.

Justman JE, Nair GL, Hendrix CW, Piper JM, Marzinke MA, Dai JY, Pan Z, Galaska B, Levy L, Schwartz JL, Balar B, Kunjara Na Ayudhya RP, Mushamiri I, McGowan I, Dezzutti CS; MTN-014 Study Team.

J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):175-182. doi: 10.1097/QAI.0000000000001655.

25.

Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data.

Rifat D, Prideaux B, Savic RM, Urbanowski ME, Parsons TL, Luna B, Marzinke MA, Ordonez AA, DeMarco VP, Jain SK, Dartois V, Bishai WR, Dooley KE.

Sci Transl Med. 2018 Apr 4;10(435). pii: eaai7786. doi: 10.1126/scitranslmed.aai7786.

26.

Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.

Hummert P, Parsons TL, Ensign LM, Hoang T, Marzinke MA.

J Pharm Biomed Anal. 2018 Apr 15;152:248-256. doi: 10.1016/j.jpba.2018.02.011. Epub 2018 Feb 8.

27.

Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study.

Grant RM, Mannheimer S, Hughes JP, Hirsch-Moverman Y, Loquere A, Chitwarakorn A, Curlin ME, Li M, Amico KR, Hendrix CW, Anderson PL, Dye BJ, Marzinke MA, Piwowar-Manning E, McKinstry L, Elharrar V, Stirratt M, Rooney JF, Eshleman SH, McNicholl JM, van Griensven F, Holtz TH.

Clin Infect Dis. 2018 May 17;66(11):1712-1721. doi: 10.1093/cid/cix1086.

28.

Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and effectiveness in an open-label demonstration project in East Africa.

Heffron R, Ngure K, Odoyo J, Bulya N, Tindimwebwa E, Hong T, Kidoguchi L, Donnell D, Mugo NR, Bukusi EA, Katabira E, Asiimwe S, Morton J, Morrison S, Haugen H, Mujugira A, Haberer JE, Ware NC, Wyatt MA, Marzinke MA, Frenkel LM, Celum C, Baeten JM; Partners Demonstration Project Team.

Version 2. Gates Open Res. 2018 Jan 30 [revised 2018 Jan 1];1:3. doi: 10.12688/gatesopenres.12752.2. eCollection 2017.

29.

Short Communication: Specimen Processing Impacts Tissue Tenofovir Pharmacokinetic Measurements.

Bakshi RP, Breakey J, Manohar M, Jois B, Fuchs EJ, Marzinke MA.

AIDS Res Hum Retroviruses. 2018 Apr;34(4):354-356. doi: 10.1089/AID.2017.0231. Epub 2018 Mar 13.

30.

Comparison of the Pharmacokinetics and Pharmacodynamics of Single-Dose Tenofovir Vaginal Film and Gel Formulation (FAME 05).

Robinson JA, Marzinke MA, Fuchs EJ, Bakshi RP, Spiegel HML, Coleman JS, Rohan LC, Hendrix CW.

J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):175-182. doi: 10.1097/QAI.0000000000001587.

31.

Hypo-osmolar Formulation of Tenofovir (TFV) Enema Promotes Uptake and Metabolism of TFV in Tissues, Leading to Prevention of SHIV/SIV Infection.

Xiao P, Gumber S, Marzinke MA, Date AA, Hoang T, Hanes J, Ensign LM, Wang L, Rohan L, Fuchs EJ, Hendrix C, Villinger F.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01644-17. doi: 10.1128/AAC.01644-17. Print 2018 Jan.

32.

Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017.

Balán IC, Giguere R, Brown W 3rd, Carballo-Diéguez A, Horn S, Hendrix CW, Marzinke MA, Ayudhya RPKN, Patterson K, Piper JM, McGowan I, Lama JR, Cranston RD; MTN-017 Protocol Team.

AIDS Behav. 2018 Mar;22(3):986-995. doi: 10.1007/s10461-017-1955-7.

33.

Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.

Bekker LG, Roux S, Sebastien E, Yola N, Amico KR, Hughes JP, Marzinke MA, Hendrix CW, Anderson PL, Elharrar V, Stirratt M, Rooney JF, Piwowar-Manning E, Eshleman SH, McKinstry L, Li M, Dye BJ, Grant RM; HPTN 067 (ADAPT) study team.

Lancet HIV. 2018 Feb;5(2):e68-e78. doi: 10.1016/S2352-3018(17)30156-X. Epub 2017 Oct 3.

34.

Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model.

Smith JM, Moss JA, Srinivasan P, Butkyavichene I, Gunawardana M, Fanter R, Miller CS, Sanchez D, Yang F, Ellis S, Zhang J, Marzinke MA, Hendrix CW, Kapoor A, Baum MM.

PLoS One. 2017 Oct 5;12(10):e0185946. doi: 10.1371/journal.pone.0185946. eCollection 2017.

35.

Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice.

Gallay PA, Chatterji U, Kirchhoff A, Gandarilla A, Gunawardana M, Pyles RB, Marzinke MA, Moss JA, Baum MM.

PLoS One. 2017 Sep 7;12(9):e0184303. doi: 10.1371/journal.pone.0184303. eCollection 2017.

36.

Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial.

Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico KR, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, McGowan I, Cottle LM, Andrade A, Marcus C, Klingman KL, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Siegel M, Manabe YC, Frank I, Ho K, Santana J, Stekler JD, Swaminathan S, McCauley M, Hodder S, Mayer KH.

Ann Intern Med. 2017 Sep 19;167(6):384-393. doi: 10.7326/M17-0520. Epub 2017 Aug 22.

37.

High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.

Carballo-Diéguez A, Balán IC, Brown W 3rd, Giguere R, Dolezal C, Leu CS, Marzinke MA, Hendrix CW, Piper JM, Richardson BA, Grossman C, Johnson S, Gomez K, Horn S, Kunjara Na Ayudhya RP, Patterson K, Jacobson C, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu A, Mayer KH, Zorrilla C, Lama J, McGowan I, Cranston RD.

PLoS One. 2017 Jul 27;12(7):e0181607. doi: 10.1371/journal.pone.0181607. eCollection 2017.

38.

Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.

Zhang Y, Clarke W, Marzinke MA, Piwowar-Manning E, Beauchamp G, Breaud A, Hendrix CW, Cloherty GA, Emel L, Rose S, Hightow-Weidman L, Siegel M, Shoptaw S, Fields SD, Wheeler D, Eshleman SH.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e02743-16. doi: 10.1128/AAC.02743-16. Print 2017 Jul.

39.

Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPT.

Sivay MV, Li M, Piwowar-Manning E, Zhang Y, Hudelson SE, Marzinke MA, Amico RK, Redd A, Hendrix CW, Anderson PL, Bokoch K, Bekker LG, van Griensven F, Mannheimer S, Hughes JP, Grant R, Eshleman SH; HPTN 067/ADAPT Study Team.

J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):271-279. doi: 10.1097/QAI.0000000000001374.

40.

Brief Report: Medication Sharing Is Rare Among African HIV-1 Serodiscordant Couples Enrolled in an Efficacy Trial of Oral Pre-exposure Prophylaxis (PrEP) for HIV-1 Prevention.

Thomson KA, Haberer JE, Marzinke MA, Mujugira A, Hendrix CW, Celum C, Ndase P, Ronald A, Bangsberg DR, Baeten JM; Partners PrEP Study Team.

J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):184-189. doi: 10.1097/QAI.0000000000001356.

41.

Correction for Lund et al., HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis.

Lund JM, Broliden K, Pyra MN, Thomas KK, Donnell D, Irungu E, Muwonge TR, Mugo N, Manohar M, Jansson M, Mackelprang R, Marzinke MA, Baeten JM, Lingappa JR.

J Virol. 2017 Jan 18;91(3). pii: e02074-16. doi: 10.1128/JVI.02074-16. Print 2017 Feb 1. No abstract available.

42.

MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel.

Cranston RD, Lama JR, Richardson BA, Carballo-Diéguez A, Kunjara Na Ayudhya RP, Liu K, Patterson KB, Leu CS, Galaska B, Jacobson CE, Parikh UM, Marzinke MA, Hendrix CW, Johnson S, Piper JM, Grossman C, Ho KS, Lucas J, Pickett J, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu AY, Mayer KH, Zorrilla C, Schwartz JL, Rooney J, McGowan I; MTN-017 Protocol Team.

Clin Infect Dis. 2017 Mar 1;64(5):614-620. doi: 10.1093/cid/ciw832.

43.

Analysis of HIV Diversity in HIV-Infected Black Men Who Have Sex with Men (HPTN 061).

Chen I, Chau G, Wang J, Clarke W, Marzinke MA, Cummings V, Breaud A, Laeyendecker O, Fields SD, Griffith S, Scott HM, Shoptaw S, Del Rio C, Magnus M, Mannheimer S, Tieu HV, Wheeler DP, Mayer KH, Koblin BA, Eshleman SH.

PLoS One. 2016 Dec 9;11(12):e0167629. doi: 10.1371/journal.pone.0167629. eCollection 2016.

44.

Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa: NIMH Project Accept (HPTN 043).

Fogel JM, Clarke W, Kulich M, Piwowar-Manning E, Breaud A, Olson MT, Marzinke MA, Laeyendecker O, Fiamma A, Donnell D, Mbwambo JK, Richter L, Gray G, Sweat M, Coates TJ, Eshleman SH, Chingono AH.

J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):158-165. doi: 10.1097/QAI.0000000000001229. Erratum in: J Acquir Immune Defic Syndr. 2018 Apr 15;77(5):e48.

45.

Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).

Gulick RM, Wilkin TJ, Chen YQ, Landovitz RJ, Amico KR, Young AM, Richardson P, Marzinke MA, Hendrix CW, Eshleman SH, McGowan I, Cottle LM, Andrade A, Marcus C, Klingman KL, Chege W, Rinehart AR, Rooney JF, Andrew P, Salata RA, Magnus M, Farley JE, Liu A, Frank I, Ho K, Santana J, Stekler JD, McCauley M, Mayer KH.

J Infect Dis. 2017 Jan 15;215(2):238-246. doi: 10.1093/infdis/jiw525.

46.

Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).

Robinson JA, Marzinke MA, Bakshi RP, Fuchs EJ, Radebaugh CL, Aung W, Spiegel HM, Coleman JS, Rohan LC, Hendrix CW.

AIDS Res Hum Retroviruses. 2017 Apr;33(4):339-346. doi: 10.1089/AID.2016.0040. Epub 2016 Dec 13.

47.

Rapid screening for targeted genetic variants via high-resolution melting curve analysis.

Chambliss AB, Resnick M, Petrides AK, Clarke WA, Marzinke MA.

Clin Chem Lab Med. 2017 Mar 1;55(4):507-516. doi: 10.1515/cclm-2016-0603.

48.

A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy.

Beigi RH, Noguchi LM, Montgomery E, Biggio J, Hendrix CW, Marzinke MA, Dai JY, Pan J, Kunjara Na Ayudhya R, Schwartz JL, Isaacs K, Piper JM, Watts DH.

J Int AIDS Soc. 2016 Sep 21;19(1):20990. doi: 10.7448/IAS.19.1.20990. eCollection 2016.

49.
50.

HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis.

Lund JM, Broliden K, Pyra MN, Thomas KK, Donnell D, Irungu E, Muwonge TR, Mugo N, Manohar M, Jansson M, Mackelprang R, Marzinke MA, Baeten JM, Lingappa JR.

J Virol. 2016 Oct 14;90(21):9855-9861. doi: 10.1128/JVI.01482-16. Print 2016 Nov 1. Erratum in: J Virol. 2017 Jan 18;91(3):.

Supplemental Content

Loading ...
Support Center